Arrowhead Pharmaceuticals Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.2% | +52.5% | -7.5% | +29.0% | -11.1% | +55.2% | -12.3% | +0.3% | +15.8% | +41.4% | -6.9% | |
| – | -43.3% | +127.7% | -16.9% | +54.5% | -18.0% | +99.0% | -16.6% | +0.4% | +23.5% | +56.7% | -9.2% | |
| – | -47.5% | +119.4% | -45.7% | +48.0% | -47.5% | +244.6% | -30.1% | +74.5% | -11.0% | -6.5% | -71.0% | |
| – | -45.4% | +137.5% | -16.5% | +55.9% | -18.8% | +98.5% | -18.0% | +2.1% | -0.3% | +94.6% | -10.2% | |
| – | – | – | – | – | – | -5.4% | +310.1% | -29.6% | +3,107.4% | -92.8% | -45.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -4.1% | -4.3% | -4.5% | -4.7% | -5.0% | -5.2% | -5.5% | -5.8% | -6.2% | -6.6% | -7.1% | |
| – | -5.4% | +1.6% | +18.5% | +74.1% | +0.9% | -7.1% | -3.2% | +2.4% | +18.1% | +60.3% | -1.4% | |
| – | -39.6% | +2.3% | +48.4% | +6.7% | -9.1% | +135.2% | -11.8% | +0.5% | +77.7% | -15.0% | -4.0% | |
| – | -67.6% | +54.5% | +14.5% | +4.8% | +29.1% | +777.0% | -34.5% | +0.6% | +0.5% | +0.5% | -16.3% | |
| – | -87.6% | +91.1% | +211.6% | -57.1% | +26.9% | -31.0% | +231.2% | -46.5% | +86.4% | -6.6% | -9.7% | |
| – | – | – | – | – | +3.7% | -48.8% | -4.1% | +7.3% | -24.1% | +416.0% | -2.1% | |
| – | -40.9% | +201.6% | -31.7% | -43.9% | -71.6% | +1,199.4% | -23.6% | -10.8% | +22.0% | +8.0% | -24.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +14.8% | +0.7% | -1.8% | +2.3% | +7.7% | +3.4% | -2.4% | +3.7% | +1.2% | +0.7% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.